DSMBi rates DSR 2.0 as safe following review of data from non-randomized cohort
Data from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapy
First patient enrolled in randomized controlled cohort expected in Q1 2024

SnoreLessNow announced today that the FDA granted 510(k) clearance for its over-the-counter dental device.

Kallisio recently announced that the FDA has cleared its 3D-printed Stentra, used to protect head and neck cancer patient’s healthy tissue during radiation therapy.

Thirona announced today that it received FDA 510(k) clearance for the latest update of its AI-based LunQ clinical software.

Pi-Cardia announced today that the FDA granted breakthrough device designation for its ShortCut leaflet modification device.

Short, toxic RNAs kill brain cells and may allow Alzheimer’s to develop

Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

The advance makes it easier to detect circulating tumor DNA in blood samples, which could enable earlier cancer diagnosis and help guide treatment.